Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Operating Expenses: 2023-2024

Historic Operating Expenses for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $50.9 million.

  • Contineum Therapeutics' Operating Expenses rose 76.18% to $17.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $50.9 million, marking a year-over-year increase of 50.03%. This contributed to the annual value of $50.9 million for FY2024, which is 50.03% up from last year.
  • As of FY2024, Contineum Therapeutics' Operating Expenses stood at $50.9 million, which was up 50.03% from $33.9 million recorded in FY2023.
  • In the past 5 years, Contineum Therapeutics' Operating Expenses ranged from a high of $50.9 million in FY2024 and a low of $33.9 million during FY2023.
  • Its 2-year average for Operating Expenses is $42.4 million, with a median of $42.4 million in 2023.
  • Data for Contineum Therapeutics' Operating Expenses shows a peak YoY soared of 50.03% (in 2024) over the last 5 years.
  • Contineum Therapeutics' Operating Expenses (Yearly) stood at $33.9 million in 2023, then spiked by 50.03% to $50.9 million in 2024.